1. Home
  2. Companies
  3. AVH
  4. Material Events

Avita Medical (ASX:AVH) — Material Events

ASX:AVH · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
AVITA Medical Cuts Skin Grafting Time by Nearly 20 Days in Interim Cohealyx StudyMedium
AVITA Medical Reports Positive Interim Cohealyx Study Results with Nearly 20-Day Reduction in Time to Skin Grafting
15 Apr 2026 ·Clinical Trial Interim Results ·85
AVITA Medical Narrows Q1 Loss as BARDA Deal and Cohealyx Data Boost Growth ProspectsMedium
AVITA Medical Q1 2026 revenue rises 4%, secures BARDA deal, Cohealyx shows faster grafting
15 May 2026 ·Financial and Business Update ·85
AVITA Medical's PermeaDerm Cuts Wound Care Costs by 70% with Comparable OutcomesMedium
AVITA Medical's PermeaDerm Study Shows 70% Cost Savings and Comparable Clinical Outcomes to Allograft
19 Aug 2026 ·Clinical Study Results ·85
AVITA Medical Posts 11% Revenue Growth, Narrows Loss Amid $60M Credit FacilityHigh
AVITA Medical reports 11% revenue growth, narrows net loss, secures $60M credit facility amid going concern doubts
13 Feb 2026 ·Annual Report and Appendix 4E ·85
AVITA Medical Raises 2026 Revenue Guidance and Targets Q4 Cash Flow BreakevenMedium
AVITA Medical raises 2026 revenue guidance with strong Q2 results and targets cash flow breakeven in Q4
7 Aug 2026 ·Quarterly Financial Update ·85
AVITA Medical Secures $60M Debt Facility, Eyes Up to 19% Revenue Growth in 2026Medium
AVITA Medical Reports 11% Revenue Growth in 2025, Secures $60M Debt Facility, Projects 12-19% Growth in 2026
14 Jan 2026 ·Preliminary Financial Results and Business Update ·85
AVITA Medical Eyes 19% Growth in 2026 After Solid Q4 PerformanceMedium
AVITA Medical posts stable Q4 2025 growth, guides $80-$85M revenue for 2026 with new debt facility
13 Feb 2026 ·Financial and Business Update ·80
AVITA Medical Eyes Growth After $60M Credit Boost and 2025 Revenue RiseMedium
AVITA Medical posts stable Q4 losses, 11% revenue growth in 2025, secures $60M credit facility, and guides for 12-19% revenue growth in 2026
13 Feb 2026 ·Financial Results ·80
AVITA Medical Navigates Revenue Growth Amid Financial Headwinds and Leadership ShiftHigh
AVITA Medical reports revenue growth, ongoing losses, credit covenant waivers, and CEO transition in Q3 2025 10-Q
7 Nov 2025 ·Form 10-Q ·80
AVITA Medical Eyes Growth After Refinancing and Clinical Progress in 2025Medium
AVITA Medical posts 2025 full-year revenue growth, improves cash flow, and secures $60M credit facility
13 Feb 2026 ·Current Report on Form 8-K ·80
AVITA Medical Unlocks European Market with CE Mark for RECELL GOMedium
AVITA Medical Secures CE Mark for RECELL GO, Launching European Commercialization
15 Sept 2025 ·Regulatory Approval Announcement ·75
AVITA Medical Names Cary Vance Interim CEO Amid $17M Q3 Revenue PreviewMedium
AVITA Medical appoints Cary Vance as Interim CEO; Q3 revenue preliminarily $17M
17 Oct 2025 ·CEO Transition and Quarterly Revenue Update ·75
AVITA Medical Narrows Losses Amid Revenue Dip and European ExpansionMedium
AVITA Medical Q3 2025 revenue down 13%, net loss narrows, lowers full-year guidance
7 Nov 2025 ·Quarterly Financial Results ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.